FDA Approves New Drug Combo for Tough-to-Treat Ovarian Cancer

(MedPage Today) -- The FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The combination of...
Source
MedPage Today
Opens original article in a new tab



